Parexel Launches ParexelAI to Accelerate CRO Clinical Development Workflows

• Parexel has launched ParexelAI, a company-wide initiative integrating artificial intelligence across its CRO clinical development and regulatory workflows.

• The platform is designed to accelerate study execution, improve operational efficiency, and support sponsors with AI-enabled decision-making across the drug development lifecycle.

Parexel announced the launch of ParexelAI, a new initiative designed to integrate artificial intelligence across its contract research organization (CRO) operations and clinical development services. The platform combines AI-enabled tools, advanced analytics, and workflow automation to support sponsors throughout the drug development lifecycle. 

The initiative builds on Parexel’s broader strategy to embed AI into clinical trial execution, regulatory consulting, patient safety, and operational workflows. According to the company, ParexelAI is intended to improve study planning, accelerate site selection, optimize enrollment strategies, and streamline data management while maintaining regulatory oversight and human review processes. 

From a CRO perspective, ParexelAI reflects increasing industry adoption of AI-native operating models aimed at reducing manual processes and improving execution efficiency. Parexel has previously expanded AI partnerships across clinical operations, pharmacovigilance, and regulatory submissions, including collaborations with Palantir, Paradigm Health, and Weave Bio. 

The company said ParexelAI is designed to create a connected digital environment capable of integrating clinical, operational, and regulatory data into AI-assisted workflows. These capabilities are expected to support faster trial execution, improved transparency, and more efficient collaboration between sponsors, sites, and CRO teams. 

“ParexelAI represents our commitment to using AI responsibly and effectively to accelerate clinical development, improve quality, and help bring therapies to patients faster.” 

Peyton Howell, Chief Executive Officer of Parexel